Projected Earnings Date: 2024-08-12    (Delayed quote data   2025-01-03)
Last
 1.10
Change
 ⇑ +0.14   (+0.00%)
Volume
  2,795,218
Open
 0.96
High
 1.16
Low
 0.96
8EMA (Daily)
 0.98
40EMA (Daily)
 1.06
50EMA (Daily)
 1.08
STO (Daily)
 48.318
MACD Hist (Daily)
 0.035
8EMA (Weekly)
 1.064
40EMA (Weekly)
 1.16
50EMA (Weekly)
 1.20
STO (Weekly)
 14.795
MACD Hist (Weekly)
 -0.056
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system?s natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body?s self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com